**Maple Syrup Urine Disease (MSUD)** results from the body’s inability to break down three amino acids: valine, leucine, and isoleucine. Initial symptoms lead to the sweet smell of maple syrup in urine, sweat, and ear wax. Without treatment for prolonged time, the build up of the three amino acids can cause brain damage, developmental delays, seizure-like spasms, and can even be fatal.1,2 1,2MSUD is more common in populations with substantial history of homozygosity, such as the Amish.3 One gene associated with MSUD is DBT. This codes for the E2 subunit of the branched chain alpha-ketoacid dehydrogenase.1 The E2 subunit has been characterized as the core protein necessary for bringing the complex together to complete the reaction and catalyzes the acyltransferase step of the reaction (2nd step).5 There have been numerous variants in the human DBT gene classified as pathogenic or likely pathogenic.6 *It is currently unknown how pathogenic DBT variants in regions not characterized to a protein domain affect the E2 protein’s catalytic function in vivo.*

My **objective** is to classify how variations in the DBT gene, specifically in regions outside of characterized protein domains affect the acyltransferase activity and/or binding ability in the E2 protein subunit. The **long term goal** of this study is to use the information on variant’s effects on the E2 protein to predict disease manifestation and progression in order to develop appropriate treatment plans based on what is not functioning correctly. I **hypothesize** that variant mutation in these regions will affect protein shape and prevent E2 from acting as the center for complex formation, thus preventing the reaction progressing further than the initial step. The mouse, *mus musculus*, and zebrafish, *danio rerio*, will be used in this study. Zebrafish when mutated at the DBT gene have shown neurologic symptoms concurrent human disease manifestation7 and can be used to see fluorescent probes on proteins and other markers. Mice have shown similar phenotypic presentation when mutant for the DBT allele8 and will be used to determine in vivo phenotypes.

**Aim 1: Define conserved amino acid sequences of known pathogenic variants in regions outside of characterized DBT protein domains in well characterized DBT homologs.**

**Approach:** NCBI Homologene will provide known homologs of the DBT gene. FASTA amino acid sequences will be obtained for relevant homologs. ClustalOmega will be used to align protein sequences. Known human pathogens will be looked at in regions that are not classified to a DBT protein domain. Those that are highly conserved will be mutated in both mice and zebrafish. Mice urine output will be obtained and analyzed for BCAA levels and zebrafish neurological manifestation will be assessed for MSUD phenotypes.

**Hypothesis**: Variations in uncharacterized protein domains that are highly conserved will lead to metabolic and neurological disease manifestation.

**Rationale:** Although not in a protein domain associated with function, there are a handful of pathogenic variants outside of those domains. If found to be highly conserved among species, those variants can be mutagenized in mice and zebrafish. If confirmed to be disease causing in the assays, those mutants can be used later to determine specific effects on the E2 protein.

**References:**

1 Strauss, K., Puffenberger, E., Morton, H. (May 2013). Maple Syrup Urine Disease. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK1319/#msud.molgen.TA>

2 National Organization for Rare Disorders. (2017). Rare Disease Data Base: Maple Syrup Urine Disease. Retrieved from <https://rarediseases.org/rare-diseases/maple-syrup-urine-disease/#supporting-organizations>

3 Abiri, M., Karamzadeh, R., Mojbafan, M., et al. (August 2016). In silico analysis of novel mutations in maple syrup urine disease patients from Iran. Retrieved from [https://link.springer.com/article/10.1007%2Fs11011-016-9867-1](https://link.springer.com/article/10.1007/s11011-016-9867-1)

4 Menkes, J. (February 1959). Maple Syrup Disease Isolation and Identification of Organic Acids in the Urine. Retrieved from <http://pediatrics.aappublications.org.ezproxy.library.wisc.edu/content/pediatrics/23/2/348.full.pdf>

5 Evarsson, A., Chuang, J., Wynn, R., et al. (March 2000). Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Retrieved from <https://www.sciencedirect.com/science/article/pii/S0969212600001052>

6 ClinVar. NCBI. (2019). Retrieved from <https://www.ncbi.nlm.nih.gov/clinvar>

7 Friedrich, T., Lambert, A.M., Masino, M.A., and Downes, G.B. (2012). Mutation of zebrafish dihydrolipoamide branched-chain transacylase E2 results in motor dysfunction and models maple syrup urine disease. Disease models & mechanisms. Retrieved from <http://zfin.org/ZDB-PUB-111115-1>

8 Homanics GE, Skvorak K, Ferguson C, Watkins S, Paul HS. (March 2006). Production and characterization of murine models of classic and intermediate maple syrup urine disease. Retreived from <https://www.ncbi.nlm.nih.gov/pubmed/16579849?dopt=Abstract>

Peinemann, F., Danner, D. (1994). Maple Syrup Urine Disease 1954 to 1993. Retrieved from [https://link-springer-com.ezproxy.library.wisc.edu/content/pdf/10.1007%2FBF00735389.pdf](https://link-springer-com.ezproxy.library.wisc.edu/content/pdf/10.1007/BF00735389.pdf)

Danner, D., Armstrong, S., Heffelfiner, E., et al. (March 1985). Absence of Branched Chain Acyl-Transferase as a Cause of Maple Syrup Urine Disease. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC423615/pdf/jcinvest00120-0092.pdf>

Danner, D., Doering, CB (June 1998). Human mutations affecting branched chain alpha ketoacid dehydrogenase. Retrieved from <https://www.bioscience.org/1998/v3/d/danner/3.htm>

Ali, E., Ngu, L. (September 2018). Fourteen new mutations of BCKDHA, BCKDHB and DBT genes associated with maple syrup urine disease (MSUD) in Malaysian population. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140420/#bb0155>

Imtiaz, F., Al-Mostafa, A., Allam, R., et al. (June 2017). Twenty novel mutations in BCKDHA, BCKDHB and DBT genes in a cohort of 52 Saudi Arabian patients with maple syrup urine disease. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388912/>

Blackburn, P. R., Gass, J. M., Vairo, F., et al. (September 2017). Maple syrup urine disease: mechanisms and management. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593394/>

Griffiths AJF, Miller JH, Suzuki DT, et al. (2000). An Introduction to Genetic Analysis. 7th edition. Recombinant DNA technology in eukaryotes. Retrieved from: <https://www.ncbi.nlm.nih.gov/books/NBK22002/>

Kohlmeir, M. (2013). Nutrigenetics. Chapter 4 – How Nutrients are affected by Genetics. Retrieved from <https://www.sciencedirect.com/science/article/pii/B9780123859006000046>